




RealRate

PHARMACEUTICAL 2022

Histogen Inc
Rank 248 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Histogen Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Histogen Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Histogen Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 35% points.

The company's Economic Capital Ratio, given in the ranking table, is 281%, being 6.1% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	21,609
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,330
Liabilities, Non-Current	4,617
Other Assets	5,237
Other Compr. Net Income	0
Other Expenses	220
Other Liabilities	112
Other Net Income	448
Other Revenues	1,032
Property and Equipment	399
Research and Development	8,473
Selling, General and Administrative Expense	7,796

Output Variable	Value in 1000 USD
Assets	27,245
Liabilities	7,059
Expenses	16,489
Revenues	1,032
Stockholders Equity	20,186
Net Income	-15,009
Comprehensive Net Income	-15,009
BaseVar	26,136
ECR before Limited Liability	169%
Economic Capital Ratio	281%